Research Article: Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies
Abstract:
Importance
There are conflicting data on the association of antidrug antibodies with response to biologic disease–modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA).
Objective
To analyze the association of antidrug antibodies with response to treatment for RA.
Design, Setting, and Participants
This cohort study analyzed data from the ABI-RA (Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients) multicentric, open, prospective study of patients with RA from 27 recruiting centers in 4 European countries (France, Italy, the Netherlands, and the UK). Eligible patients were 18 years or older, had RA diagnosis, and were initiating a new bDMARD. Recruitment spanned from March 3, 2014, to June 21, 2016. The study was completed in June 2018, and data were analyzed in June 2022.
Exposures
Patients were treated with a new bDMARD: adalimumab, infliximab (grouped as anti–tumor necrosis factor [TNF] monoclonal antibodies [mAbs]), etanercept, tocilizumab, and rituximab according to the choice of the treating physician.
No summary available.